Skip to content

Evaluation of the FAST-M maternal sepsis bundle

Evaluation of the FAST-M maternal sepsis bundle: a feasibility study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN87339737
Enrollment
240
Registered
2017-12-13
Start date
2017-06-05
Completion date
Unknown
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maternal sepsis Pregnancy and Childbirth

Interventions

Component 1: introduction of a modified early obstetric warning score to enable the observation of patients to be recorded and also the FAST-M decision tool to enable recognition of maternal sepsis

Sponsors

University of Birmingham
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Women who are pregnant or within 6 weeks of miscarriage, termination of pregnancy or delivery 2. Receiving either inpatient or outpatient health care

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

MeasureTime frame
1. Fidelity: Time to bundle completion after recognition of sepsis. Data will be collected using specifically designed case report forms (CRFs). Data will be measured continually throughout baseline and intervention phase. 2. Number of training refresher courses: How often healthcare practitioners require training refresher sessions. Data will be measured continually throughout intervention phase. 3. Acceptability: Barriers to healthcare workers using the FAST-M toolkit. Data will be collected using a mix of semi-structured interviews and focus groups. This data will be measured at 1 month, 5 month and 6 months of intervention study. 4. Adoption: How well each healthcare facility adopts the intended practice. Data will be collected using a mix of semi-structured interviews, focus groups, CRF data collection and spot audits. Mixed method analysis using qualitative and quantitative assessment will be used to derive an overall assessment of the level of adoption. Quantitative data (spot audits and CRF data collection) will be measured continually throughout the intervention phase. Qualitative data (semi-structured interviews and focus groups) will be conducted at 1, 5 and 6 months of intervention study 5. Appropriateness: Is the intervention required at the study site and is it clinically relevant? Data will be collected using a mix of semi-structured interviews and focus groups. This data will be measured at 1, 5 and 6 months of intervention study. 6. Feasibility: Ability to achieve each element of the treatment bundle within the specified time limit. Data will be collected using a mix of semi-structured interviews, focus groups, CRF data collection and spot audits. Mixed method analysis using qualitative and quantitative assessment will be used to derive an overall assessment of the level of feasibility. Quantitative data (spot audits and CRF data collection) will be measured continually

Secondary

MeasureTime frame
1. Pregnancy outcome: Live birth, still birth, miscarriage, induced abortion, ectopic. Data collected continually throughout study 2. Maternal morbidity: Maternal in-hospital morbidity. Data collected continually throughout study 3. Maternal mortality: Maternal in-hospital mortality. Data collected continually throughout study 4. Maternal length of stay in days. Data collected continually throughout study 5. Maternal near miss events: As defined by the WHO near miss events. Data collected continually throughout study 6. Neonatal APGAR scores at 5 minutes. Data collected continually throughout study 7. Neonatal length of stay in days. Data collected continually throughout study 8. Neonatal need for antibiotics: Whether the neonate received antibiotics. Data collected continually throughout study 9. Admission to neonatal unit: Whether the neonate was admitted to a neonatal unit. Data collected continually throughout study Other pre-specified outcome measures: 10. Theory of Change model: To prepare the FAST-M intervention for a large scale trial. Data collected continually throughout study

Countries

Malawi

Contacts

Public ContactJames Cheshire

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026